TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04989205

Intervention type: BEHAVIORAL
Intervention: Cannabis cessation Program
Description: Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
Study: NCT00087256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01232166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auscultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auscultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation of symmetric chest movements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation of symmetric chest movements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tube depth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tube depth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All three

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All three
Study: NCT03950206

Intervention type: OTHER
Group type: OTHER
Intervention: Indocyanine green angiography
Description: Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
Study: NCT01503606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin 1.0gm IVs q 12 hours after randomization for one week
Study: NCT03455985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge Order Set (DOS)
Description: In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Standard Care (ESC)
Description: Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
Study: NCT02746107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: decision aid
Description: decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
Study: NCT01992965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different methods of blood glucose monitoring between groups
Description: Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different methods of blood glucose monitoring between groups
Description: Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
Study: NCT00307216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graduated Recovery Intervention Program (GRIP)
Description: GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
Study: NCT01788371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
Study: NCT01450007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 25 ml ropivacaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 25 ml ropivacaine 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 25 ml ropivacaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg dexamethasone (perineural)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 5 ml normal saline (intravenous)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 ml normal saline (intravenous)
Study: NCT02505009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Both case and control will receive 300 mg Tenofovir for at least 3 years
Study: NCT01450007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.8 ml normal saline (perineural)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.8 ml normal saline (perineural)
Study: NCT03642834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-105
Description: 25mg, 100mg capsule
Study: NCT02435485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex balance training
Description: 1.weight shift training, 2. random control training with Biodex balance system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation including core spinal stabilization exercise
Description: Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation including core spinal stabilization exercise
Description: Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation including core spinal stabilization exercise
Description: Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
Study: NCT02505009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Both case and control will receive 0.5 mg entecavir therapy for at least 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
Study: NCT03441490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided-ICBT for adolescents with anxiety
Description: Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
Study: NCT04312061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tramadol
Description: oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: oral placebo tablet given 1 hour before LNG-IUD insertion
Study: NCT01108068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
Study: NCT01896466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Nerve Non-Invasive Neuromodulation
Description: Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Nerve Non-Invasive Neuromodulation
Description: Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
Study: NCT01432886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
Study: NCT01503606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: clarithromycin 500mg po bid after randomization for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin 1.0gm IVs q 12 hours after randomization until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: clarithromycin 500mg po bid after randomization until delivery
Study: NCT00746265

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss intervention
Description: Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss intervention
Description: Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
Study: NCT02908646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microcoil localization
Description: CT-guided localization by placing a microcoil into the lung parenchyma

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hookwire localization
Description: CT-guided localization by placing a hookwire into the lung parenchyma
Study: NCT03711929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-109 Intravitreal Injections
Description: 440 ug of DE-109 Injectable Solution

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham procedure mimics an intravitreal injection without penetrating the eye.

Intervention type: DRUG
Group type: OTHER
Intervention: DE-109 Intravitreal Injections
Description: Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-109 Intravitreal Injections (Open Label)
Description: After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
Study: NCT01896466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Nerve Non-Invasive Neuromodulation
Description: Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Cranial Nerve Non-Invasive Neuromodulation
Description: Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cranial Nerve Non-Invasive Neuromodulation
Description: Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Cranial Nerve Non-Invasive Neuromodulation
Description: Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
Study: NCT04155190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel, 2%
Description: Patidegib Topical Gel, 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patidegib Topical Gel, Vehicle
Description: Patidegib Topical Gel, Vehicle
Study: NCT03371004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Description: IV administration as described
Study: NCT03838666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of human autologous MSC 3P
Description: Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
Study: NCT02604628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic Stewardship Intervention
Description: The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
Study: NCT01007318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single port laparoscopic appendectomy
Description: Single port through the transumbilical 2-cm incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 port laparoscopic appendectomy
Description: 3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
Study: NCT01425528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
Study: NCT03784716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss Diet
Description: Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
Study: NCT01738724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: Dienogest 2mg pills daily during 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel
Description: Desogestrel 75mcg pills daily during six months
Study: NCT03256123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red palm shortening group
Description: Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain \~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill \~70% of the RNI of vitamin A for children aged 7-11 years old.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: palm shortening group
Description: Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
Study: NCT02394366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Original Healing Salve (OHS)
Description: Topical salve (Puremedy, Inc.)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OHS base only
Description: Olive and beeswax salve base
Study: NCT01582191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT03441490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided-ICBT with chat
Description: Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
Study: NCT01582191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Given PO
Study: NCT03459105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted paramedian spinal anesthesia
Description: A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guided spinal anesthesia
Description: Spinal anesthesia will be done using conventional landmark-guided technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% heavy bupivacaine
Description: 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.